Search

VXA-CoV2-1

VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. … This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell

IN01

Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130). … These cultures contain EGF-4-EGF with the cholera toxin B-subunit domain G33D sequence[L30543].

AdimrSC-2f

The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553]. … A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].

Ganulameran

As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology.

Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. … These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants.

UB-612

The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … In rats, toxicity studies have so far shown favourable safety for this vaccine[L30653, L30658], Phase 1 trial is currently ongoing in Taiwan (NCT04545749).

Thymoquinone

Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.

Efprezimod alfa

CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.

Rexin G

Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. … It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.

MAS825